Del-Sette Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Del-Sette Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-62,494	Closed	-$4.05M	–	56
2025 Q3	$4.05M	Sell	62,494 -1,349	-2%	-$77.4K	2.52%	13
2025 Q2	$3.11M	Buy	+63,843	New	+$2.47M	2.16%	22
2024 Q3	–	Sell	-36,841	Closed	-$1.99M	–	36
2024 Q2	$1.99M	Buy	+36,841	New	+$2.13M	1.63%	20
2023 Q4	–	Sell	-33,977	Closed	-$1.54M	–	29
2023 Q3	$1.54M	Buy	33,977 +316	+0.9%	+$16.3K	1.52%	16
2023 Q2	$1.89M	Buy	33,661 +9,867	+41%	+$560K	1.79%	16
2023 Q1	$1.08M	Buy	+23,794	New	+$1.16M	1.06%	20

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GSK plc London $599M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Del-Sette Capital Management's CRSP Position: Q4 2025 in Review

Del-Sette Capital Management sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 62,494 shares — an estimated $4.05M sold.

Del-Sette Capital Management first reported a position in CRSP in Q1 2023 and held it in 6 quarters. The position peaked at $4.05M in Q3 2025. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

Del-Sette Capital Management reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
Del-Sette Capital Management sold 62,494 CRISPR Therapeutics shares in Q4 2025, an estimated $4.05M.
Del-Sette Capital Management first reported a position in CRISPR Therapeutics in Q1 2023 and held it in 6 quarters.
Del-Sette Capital Management's CRISPR Therapeutics position peaked at $4.05M in Q3 2025.
479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Del-Sette Capital Management's 13F filing for Q4 2025, filed 2 Feb 2026.